CollabRx enabling the emerging Personal Economy

There’s much work to do, but approaches like CollabRX are giving patients reason to hope where previously little or none existed. – Bruce Kasanoff, founder and editor of ‘Now Possible: Charting the emerging Personal Economy’.Read More

A Mother's Bid to Stop 'Childhood Alzheimer's'

CollabRx founder, Marty Tenenbaum, is featured in this short video describing how CollabRx helped the parents of Addi and Cassi Hempel organize research to fight Niemann-Pick C, a devastating disease sometimes called "childhood Alzheimer's". Read More

Marty Tenenbaum shares his journey fighting melanoma to help empower patients

Read More

CollabRx ONE, TREAT1000: The Cancer Connection

Marty Tenenbaum interviewed on "Open Source Science"

CollabRx Debuts Cancer Genomics Service to Distinguish Itself from DTC Genomics Firms

With the launch of CollabRx One, CollabRx hopes to advance the "discovery of new therapies by aggregating the learning from every patient."

Research Consortium, Testing Service Hope to Turn Cancer Genome Analyses into Rx Selections

According to CollabRx's Tenenbaum, the project serves a dual purpose: generating research results and funneling them back to study participants. "You can really think about this as personalized research, but also aggregating the results to drive the field," he said.

CollabRx Launches Personal Genomics Service to Target 'Long Tail' of Disease

Tenenbaum described the company's model as a way to address the "huge unmet medical need in the long tail of disease," referring to the large population of patients that are "not within pharma's economic target market" because they do not respond to current treatment regimens.

Tenenbaum Urges Collaboration to Treat the Long Tail of Disease

CollabRx aims to leverage the extraordinary untapped expertise and resources across the industry to empower individual patient healthcare through personalized research.

CollabRx, Alacris Partner on Cancer Sequencing Project

CollabRx and Alacris Pharmaceuticals will work together on TREAT 1000, a project that will "create a compendium of cancer genome information that will inform future research and treatment."

CollabRx Launches New Service CollabRx ONE

CollabRx announced the launch of its new personalized cancer research service, CollabRx ONE, designed to provide physicians with new insights into specific treatment options for their cancer patients.

CollabRx ONE Personalized Cancer Research

"CollabRx ONE scientists look at 15,000 genes simultaneously, in the context of a patient’s full medical situation, and adds advanced technologies to find evidence supporting the potential use of any of the 5,000 approved pharmaceutical therapies and possible investigational compounds." Dr. Tenenbaum explained.

Therapy Development in a Networked World

CollabRx founder Marty Tenenbaum presented the keynote address at Cambridge Healthtech Institute's 16th annual Molecular Medicine Tri-Conference (TriCon): "Therapy Development in a Networked World."

Download Dr. Tenenbaum's keynote presentation (PDF)

Models of Change: CollabRx

"There are increasing opportunities to share data, expertise, and services across industry and academia that will rapidly advance the pace of drug discovery and development." – Dr. Marty Tenenbaum

"Big Pharma is trapped in a business model that requires the type of large patient populations for blockbuster drugs that are directly countermanded by our increasing understanding of personalized medicine." – Dr. Catherine Ley

CollabRx facilitates collaborations between researchers of Niemann-Pick Type C

The purpose is to find therapies faster by getting scientists to develop a targeted strategy for doing so, share ideas and data, and making sure no one doubles another's efforts.

CollabRx's software platform lets them share data and ideas remotely.

Discovering Virtual Pharma

The greatest benefit is obviously vastly accelerated therapy development and being able to facilitate and accelerate both R&D in drugs and other therapies.

Commerce has gone to an Internet-based supply-chain workflow management model, and it's just a small step to make the equivalent move in a science-based industry.

CollabRx named in FasterCures "Ten to Watch in 2008" Mid-Year Review

CollabRx demonstrated a Web-based collaborative research platform that would enable funding organizations and research teams to manage, track, and prioritize their operations as well as to share data, knowledge, resources, and services.

Putting Drug Development in Patients' Hands

CollabRx aims to expand patient-funded research further by connecting individuals or small numbers of patients with the tools and services they need.

Researchers in various locations can share information and material by means of a Web-based network created by CollabRx software engineers.

Dr. Donald Kennedy to lead CollabRx Scientific Advisory Board

Dr. Donald Kennedy, President emeritus at Stanford University, former editor-in-chief of Science, and FDA Commissioner under President Carter, will chair the Scientific Advisory Board at CollabRx.

Health Commons: Therapy Development in a Networked World

The time has come to change the way we cure disease. We are no longer asking whether a gene or a molecule is critical to a particular biological process; rather, we are discovering whole networks of molecular and cellular interactions that contribute to disease.

Cancer Survivor Pitches 'Virtual' Drug Firms

"The only people with the compelling interest to invest in the cures of these diseases are the people with the diseases," Tenenbaum said.

"Virtual pharmas" can shorten the time it takes to find out which drugs work - and which don't.

CollabRx - Accelerating the discovery of effective treatments and permanent cures (PDF)

CollabRx applies collaborative science to slash the time, cost and risk of therapy development.

Marty Tenenbaum presents “Therapy Development in a Networked World”

Health Commons: An e-Business Approach to Collaborative Therapy Development

Marty Tenenbaum presents the Luncheon Keynote address at Cambridge Healthtech Institute's “Collaborative Innovation in Biomedicine” conference.

Competitive models of drug discovery and development are broken -- not just failing to discover new blockbuster drugs, but failing to contribute meaningful research that can be leveraged to develop more personalized, molecularly targeted therapies. Conventional consortia, while useful, are themselves silos, limited in their ability to broadly share findings and infrastructure, and thus to impact commercial drug development. What’s needed is nothing less than reworking the entire business model for therapy development – processes, economics and culture -- into a thoroughly collaborative model that exploits the spectacular breakthroughs in genomics and information technology to slash the time, costs and risks of therapy development. Health Commons is doing just that, through an ecosystem of knowledge and research services that can be rapidly assembled to develop therapies for patients with serious unmet medical needs. Health Commons aims to create the same radical increase in efficiency for therapy development that commerce saw in the 1990s.

Personalized Molecular Medicine: The turning point in fighting cancer

Amos Barzilay discussed the current state of the fight against cancer as well as potential business opportunities in personalized medicine at the Silicom Summit on personalized medicine

Marty Tenenbaum shares his journey fighting melanoma to help empower patients

Collaborative Research Infrastructure

Marty Tenenbaum presents the Keynote address at the Collaborative Cures Summit in the 4th Neurotech Industry Investing and Partnering Conference

The development of web-based collaborative communities like Alzforum and NeuroCommons suggest that it is possible to create network effects to accelerate the development treatments and cures. What are the bottlenecks to broad adoption of these collaborative technologies? How can semantic web technologies be used to radically improve data sharing and collaboration? How can these platforms be used to support breakthrough research across diseases? Read More

2009 AMIA Translational Bioinformatics Conference

Marty Tenenbaum participated in the 2008 AMIA Summit on Translational Bioinformatics in San Francisco, California, March 10 - 12, where the latest progress on using informatics approaches to improve translational biomedical research was presented. Read MoreCoverage of this summit by genomeweb